1
|
Wiśniewski K, Alagarsamy S, Galyean R, Tariga H, Thompson D, Ly B, Wiśniewska H, Qi S, Croston G, Laporte R, Rivière PJM, Schteingart CD. New, Potent, and Selective Peptidic Oxytocin Receptor Agonists. J Med Chem 2014; 57:5306-17. [DOI: 10.1021/jm500365s] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- Kazimierz Wiśniewski
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| | - Sudarkodi Alagarsamy
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| | - Robert Galyean
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| | - Hiroe Tariga
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| | - Dorain Thompson
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| | - Brian Ly
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| | - Halina Wiśniewska
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| | - Steve Qi
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| | - Glenn Croston
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| | - Regent Laporte
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| | - Pierre J.-M. Rivière
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| | - Claudio D. Schteingart
- Ferring Research Institute Inc., 4245 Sorrento Valley Boulevard, San Diego, California 92121, United States
| |
Collapse
|
2
|
|
3
|
Bellenie BR, Barton NP, Emmons AJ, Heer JP, Salvagno C. Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design. Bioorg Med Chem Lett 2008; 19:990-4. [PMID: 19095447 DOI: 10.1016/j.bmcl.2008.11.064] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2008] [Revised: 11/17/2008] [Accepted: 11/18/2008] [Indexed: 10/21/2022]
Abstract
A novel oxytocin antagonist was identified by 'scaffold-hopping' using Cresset FieldScreen molecular field similarity searching. A single cycle of optimization driven by an understanding of the key pharmacophoric elements required for activity led to the discovery of a potent, selective and highly ligand-efficient oxytocin receptor antagonist. Selectivity over vasopressin receptors was rationalized based on differences in the structure of the natural ligands.
Collapse
Affiliation(s)
- Benjamin R Bellenie
- GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park (North), Coldharbour Road, Harlow, Essex CM19 5AD, England, United Kingdom.
| | | | | | | | | |
Collapse
|